National Guideline Clearinghouse | Chemotherapy (i.e., gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma.

full-text ►

National Guideline Clearinghouse | Chemotherapy (i.e., gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma.

Program in Evidence-based Care

Cancer Care Ontario (CCO

Guideline Title

Chemotherapy (i.e., gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma.

Bibliographic Source(s)

Gupta A, Yao X, Verma S, Mackay H, Hopkins L, Sarcoma Disease Site Group (DSG), Gynecology Cancer DSG. Chemotherapy (i.e., gemcitabine, docetaxel plus gemcitabine, doxorubicin, or trabectedin) for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma. Toronto (ON): Cancer Care Ontario (CCO); 2012 Jul 18. 41 p. (Evidence-based series; no. 11-11).  [37 references]

Guideline Status

This is the current release of the guideline.

The EVIDENCE-BASED SERIES report, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities.

Please visit the Cancer Care Ontario Web site  for details on any new evidence that has emerged and implications to the guidelines.